Advertisement

Topics

BMS snaps up cancer biotech IFM in $2.3bn deal

09:04 EDT 4 Aug 2017 | pharmaphorum

Bristol-Myers Squibb is to buy biotech IFM Therapeutics, and its potential new cancer immunotherapy technology, in a deal that could be worth more than $2.3 billion. BMS will gain rights to IFM’s preclinical stimulator of interferon genes (STING...

Original Article: BMS snaps up cancer biotech IFM in $2.3bn deal

NEXT ARTICLE

More From BioPortfolio on "BMS snaps up cancer biotech IFM in $2.3bn deal"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...